<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Liquidia Technologies, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Liquidia Technologies, Inc.

    Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary PRINT technology to transform the lives of patients. Currently, Liquidia is focused on the development of two product candidates using its PRINTÂŽ particle engineering platform: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $166,000,000
    • SIC CODE
      3841
    • NIN CODE
      ####
    • LEADERSHIP
      Neal Fowler
    • FOUNDED
      2004
    • EMPLOYEES
      51-100
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    The Medicines Company

    The Medicines Company

    The Medicines Company is a biopharmaceutical company driven by an overriding purpo...

    The Medicines Company is a biopharmaceutical co...

    Filing Type:    PU
    Phio Pharmaceuticals Corp.

    Phio Pharmaceuticals Corp.

    Phio Pharmaceuticals is focused on developing the next generation of immuno-oncolo...

    Phio Pharmaceuticals is focused on developing t...

    Filing Type:    PU
    Unity Biotechnology, Inc.

    Unity Biotechnology, Inc.

    UNITY Biotechnology is developing therapeutics to extend human healthspan by slowi...

    UNITY Biotechnology is developing therapeutics ...

    Filing Type:    PU
    Verax Research Services, Inc.

    Verax Research Services, Inc.

    Knowledge Begets Confidence. Founded by proven and trusted Pharmaceutical and Medi...

    Knowledge Begets Confidence. Founded by proven ...

    Filing Type:    RA
    Otsuka Holdings Co. Ltd.

    Otsuka Holdings Co. Ltd.

    Otsuka Holdings Co Ltd is a pharmaceutical company. The Company manufactures, sell...

    Otsuka Holdings Co Ltd is a pharmaceutical comp...

    Filing Type:    PU
    Foamix Pharmaceuticals Ltd.

    Foamix Pharmaceuticals Ltd.

    Foamix Pharmaceuticals is a specialty pharmaceutical company, committed to address...

    Foamix Pharmaceuticals is a specialty pharmaceu...

    Filing Type:    PU
    Dicerna Pharmaceuticals, Inc.

    Dicerna Pharmaceuticals, Inc.

    Dicerna is a biopharmaceutical company focused on the discovery and development of...

    Dicerna is a biopharmaceutical company focused ...

    Filing Type:    PU
    LivaNova PLC

    LivaNova PLC

    LivaNova is a global medical technology company built on decades of experience and...

    LivaNova is a global medical technology company...

    Filing Type:    PU
    CohBar, Inc.

    CohBar, Inc.

    CohBar, Inc. is a leader in the research and development of mitochondria based the...

    CohBar, Inc. is a leader in the research and de...

    Filing Type:    PU
    JanOne Inc.

    JanOne Inc.

    JanOne, formerly Appliance Recycling Centers of America, Inc., and subsidiaries, i...

    JanOne, formerly Appliance Recycling Centers of...

    Filing Type:    PU
    Insitu Biologics, Inc

    Insitu Biologics, Inc

    InSitu Biologics is an emerging biotech company focusing on development of AnestaG...

    InSitu Biologics is an emerging biotech company...

    Amount Raised:    $2,000,000.00
    Fundraising Status:    EC
    Filing Type:    RA
    Neurocarrus Inc

    Neurocarrus Inc

    Neurocarrus is developing a breakthrough therapy ( N-001 ) to fulfill the unmet ne...

    Neurocarrus is developing a breakthrough therap...

    Amount Raised:    $344,168.00
    Fundraising Status:    EC
    Filing Type:    CF
    ©2026 National Investor Network. All Rights Reserved.